BioSpace News Archive

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce it has filed a new Offering Document

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on September 29, 2023.

, the U.S. Food and Drug Administration granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers.

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office relating to the challenge to the Company’s European patent, has been cancelled.

Annexin Pharmaceuticals announces important progress in the company’s preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.

SOPHiA GENETICS announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform.

Synlogic, Inc. announced the pricing of an underwritten public offering of 7,394,363 shares of common stock and accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.

Theralase® Technologies Inc. is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds, their associated drug formulations and the light systems that activate them.

Capricor Therapeutics announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy.